Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib

Yang, Da; Chen, Feng; Gong, Dan; Zeng, Lei; Ding, Xuanming; He, Yakun; Chen, Leifeng; Yan, Jing; Zhang, Shouhua

doi:10.1007/s00383-021-05043-5

Cited by 2 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this investigation, a previously reported HB PDX model was utilized (Yang et al, 2022). The PDX experiments were approved by the Ethics Committee of The Affiliated Children's Hospital of Nanchang Medical College and conducted in accordance with relevant laws and regulations.…”

Section: Methodsmentioning

confidence: 99%

“…In this investigation, a previously reported HB PDX model was utilized (Yang et al, 2022). The PDX experiments were approved Mice received intraperitoneal injections of cisplatin (5 mg/kg, once a week) (Hansoh Pharma) (Murakami et al, 2017), serving as the positive control drug due to its integral role in HB chemotherapy (Wu & Rangaswami, 2022;Zsiros et al, 2013).…”

Section: In Vivo Experimental Grouping and Treatmentmentioning

confidence: 99%

“…Although they share similar structures, there are significant differences in their pharmacokinetics, pharmacodynamics, and toxicokinetic properties (Yang et al, 2017). In the preliminary experiments, we successfully established an HB patient‐derived xenograft (PDX) model (Yang et al, 2022), and observed a remarkable antitumor effect of everolimus. Therefore, this study aims to elucidate the anti‐HB effect of everolimus, as well as its induction of autophagy‐dependent ferroptosis both in vitro and in vivo.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Everolimus inhibits hepatoblastoma by inducing autophagy‐dependent ferroptosis

Huang,

Yan,

et al. 2023

Drug Development Research

Self Cite

View full text Add to dashboard Cite

Everolimus, a known inhibitor of the mammalian target of rapamycin (mTOR), has shown uncertain efficacy in treating hepatoblastoma. This study delves into the potential anti‐hepatoblastoma properties of everolimus and its intricate relationship with autophagy and ferroptosis, both in vitro and in vivo. In vivo, tumor tissue from hepatoblastoma patient and human hepatoblastoma cell line HuH‐6 were xenografted into nude mice to establish xenograft models for observing the effect of everolimus on tumor growth. In vitro, HuH‐6 cells were cultured to evaluate the anti‐hepatoblastoma activity of everolimus. Transmission electron microscopy and microtubule‐associated proteins 1 light chain 3 (LC3), beclin 1, and p62 protein expressions were employed to investigate autophagy. Additionally, indicators of cell apoptosis, reactive oxygen species (ROS) and proteins associated with ferroptosis were measured to evaluate ferroptosis. The results demonstrate that everolimus treatment effectively induced the formation of autophagosomes in hepatoblastoma cells, upregulated the LC3II/I ratio and beclin 1 expression, and downregulated p62 expression, indicating an enhanced autophagy level both in vitro and in vivo. Furthermore, everolimus treatment induced cell apoptosis, increased ROS level, elevated concentrations of malondialdehyde, 4‐hydroxynonenal, and iron content, while reducing the ratio of glutathione/oxidized glutathione, and downregulating the protein expression of glutathione peroxidase 4 and solute carrier family 7 member 11, suggesting its ability to induce ferroptosis in hepatoblastoma cells. Importantly, the induction of ferroptosis by everolimus was significantly reversed in the presence of autophinib, an autophagy inhibitor, indicating the autophagy‐dependent of everolimus‐induced ferroptosis. Taken together, these findings suggest that everolimus holds promise as an effective anti‐hepatoblastoma drug, with its mechanism of action potentially involving the induction of autophagy‐dependent ferroptosis in hepatoblastoma cells.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: In Vivo Experimental Grouping and Treatmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Everolimus inhibits hepatoblastoma by inducing autophagy‐dependent ferroptosis

Huang,

Yan,

et al. 2023

Drug Development Research

Self Cite

View full text Add to dashboard Cite

show abstract

Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study

Wang,

Mao,

Yang

et al. 2023

Future Oncol.

View full text Add to dashboard Cite

Objective: To investigate the safety and efficacy of anlotinib hydrochloride capsules in stage III–IV non-small-cell lung cancer (NSCLC). Methods: NSCLC patients received anlotinib monotherapy or combination therapy. The primary end point was adverse reactions during anlotinib treatment and the secondary end point was progression-free survival. Results: During anlotinib treatement, 41.85% (167/399) of patients experienced adverse reactions, and the monotherapy group had a lower incidence than the combination group (36.89 vs 49.68%; p = 0.012). The median progression-free survival of patients in the monotherapy group was significantly lower than that in the combination group (5 vs 6 months; p = 0.0119). Conclusion: Compared with anlotinib monotherapy, combination therapy resulted in longer PFS and a higher incidence of adverse reactions in patients with NSCLC.

show abstract

Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib

Cited by 2 publications

References 29 publications

Everolimus inhibits hepatoblastoma by inducing autophagy‐dependent ferroptosis

Everolimus inhibits hepatoblastoma by inducing autophagy‐dependent ferroptosis

Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study

Contact Info

Product

Resources

About